发明授权
US06916813B2 (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
有权
（1-苯基-2-单芳基）乙基胍化合物作为线粒体F1F0 ATP水解酶的抑制剂
- 专利标题： (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
- 专利标题（中）： （1-苯基-2-单芳基）乙基胍化合物作为线粒体F1F0 ATP水解酶的抑制剂
-
申请号： US10315818申请日： 2002-12-10
-
公开(公告)号： US06916813B2公开(公告)日： 2005-07-12
- 发明人: Karnail S. Atwal , Gary J. Grover , Charles Z. Ding , Philip D. Stein , John Lloyd , Saleem Ahmad , Lawrnce G. Hamann , David Green , Francis N. Ferrara
- 申请人： Karnail S. Atwal , Gary J. Grover , Charles Z. Ding , Philip D. Stein , John Lloyd , Saleem Ahmad , Lawrnce G. Hamann , David Green , Francis N. Ferrara
- 申请人地址： US NJ Princeton
- 专利权人： Bristol-Myers Squibb Co.
- 当前专利权人： Bristol-Myers Squibb Co.
- 当前专利权人地址： US NJ Princeton
- 代理商 Laurelee A. Duncan
- 主分类号： A61P9/00
- IPC分类号： A61P9/00 ; C07D231/12 ; C07D233/54 ; C07D235/06 ; C07D235/10 ; C07D235/14 ; C07D249/08 ; C07D401/12 ; C07D403/12 ; C07D405/12 ; C07D409/12 ; C07D413/12 ; C07D417/12 ; C07D521/00 ; A01N43/50 ; A61K31/415
摘要：
Compounds having the formula (I), and pharmaceutically acceptable salts thereof, are useful for modulating mitochondrial F1F0 ATPase activity and treating ischemic conditions including myocardial infarction, congestive heart failure, and cardiac arrhythmias.